Monitor for the outcome of the shareholder vote on the share capital increase and executive compensation, as these could have future implications for share dilution and governance.
Price Chart
Executive Summary
Can-Fite BioPharma is holding its 2026 Annual General Meeting of Shareholders, where shareholders will vote on re-electing a director, increasing authorized share capital, approving stock option grants to executives, re-appointing auditors, and reviewing financial statements. This is a routine annual meeting with no material financial data disclosed.
Key Facts
- Proposing to re-elect Abraham Sartani to the Board of Directors
- Proposing to increase authorized share capital from 14 million to 30 million ordinary shares
- Proposing to grant options to Chairman Dr. Pnina Fishman and CEO Motti Farbstein
- Proposing to re-appoint Kost Forer Gabbay & Kasierer as independent auditors
- Board recommends voting FOR all proposals
Financial Impact
Undisclosed amount for option grants and potential future capital raises from increased share capital
Risk Factors
- Potential share dilution from increased authorized capital
- Executive compensation decisions may not align with shareholder interests
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047088 |
| Document: ea0287474-6k_canfite.htm | 0001213900-26-047088 |
| Document: ea028747401ex99-2.htm | 0001213900-26-047088 |
| Document: ea028747401ex99-3.htm | 0001213900-26-047088 |
| Document: 0001213900-26-047088-index-headers.html | 0001213900-26-047088 |
| Document: 0001213900-26-047088-index.html | 0001213900-26-047088 |
| Document: 0001213900-26-047088.txt | 0001213900-26-047088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.72 (−11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers